ARS Pharmaceuticals (SPRY) Cash & Current Investments (2020 - 2026)

ARS Pharmaceuticals has disclosed Cash & Current Investments across 7 years of filings, most recently posting $201.0 million for Q1 2026.

• Cash & Current Investments for Q1 2026 came in at $201.0 million, down 27.11% year-over-year; the trailing twelve-month figure through Mar 2026 was $201.0 million (down 27.11% YoY), and the FY2025 annual result was $245.0 million, down 21.98% from the prior year.
• Cash & Current Investments came in at $201.0 million for Q1 2026 at ARS Pharmaceuticals, down from $245.0 million in the prior quarter.
• In the past five years, Cash & Current Investments ranged from a high of $314.0 million in Q4 2024 to a low of $201.0 million in Q1 2026.
• The 5-year median for Cash & Current Investments is $252.2 million (2023), against an average of $250.1 million.
• Peak annual rise in Cash & Current Investments reached 356.82% in 2022, while the deepest fall reached 32.16% in 2022.
• ARS Pharmaceuticals' Cash & Current Investments stood at $274.4 million in 2022, then slipped by 16.77% to $228.4 million in 2023, then surged by 37.51% to $314.0 million in 2024, then retreated by 21.98% to $245.0 million in 2025, then fell by 17.97% to $201.0 million in 2026.
• The last three Cash & Current Investments figures came in at $201.0 million (Q1 2026), $245.0 million (Q4 2025), and $288.2 million (Q3 2025), per Business Quant data.